NEWS CENTER

Position:

Group Announcement

Media reports

Group News

Shijiazhuang Four Pharmaceutical’s two products successfully won bids in the fifth round of national centralized procurement.

Category:

Group Announcement

Time：2021-06-24

On June 23, the fifth round of nationwide centralized drug procurement—highly anticipated by the pharmaceutical industry—officially kicked off with bid opening in Shanghai. Two product specifications manufactured by Shijiazhuang Sihua Pharmaceutical Co., Ltd., a major pharmaceutical enterprise in our province, successfully won bids: Fluconazole Sodium Chloride Injection (100 ml: 0.2 g fluconazole and 0.9 g sodium chloride) and Ropivacaine Hydrochloride Injection (10 ml: 100 mg in polypropylene ampoules). Currently, Shijiazhuang Sihua Pharmaceutical has had six varieties and nine product specifications included in the national centralized drug procurement program.

On June 23, the fifth round of nationwide centralized drug procurement—highly anticipated by the pharmaceutical industry—officially kicked off with bid opening in Shanghai. Two product specifications manufactured by Shijiazhuang Sihua Pharmaceutical Co., Ltd., a major pharmaceutical enterprise in our province, successfully won bids: Fluconazole Sodium Chloride Injection (100 ml: 0.2 g fluconazole and 0.9 g sodium chloride) and Ropivacaine Hydrochloride Injection (10 ml: 100 mg in polypropylene ampoules). Currently, Shijiazhuang Sihua Pharmaceutical has had a total of 6 varieties and 9 product specifications included in the national centralized drug procurement program.

It is reported that the fifth round of nationally organized centralized drug procurement involves 62 drug varieties—the largest number of varieties ever included in such a procurement. In terms of dosage forms, this round of centralized procurement covers a total of 30 injectable drug varieties, accounting for nearly 50% of the total. The total market sales of these injectables in 2020 amounted to 40 billion yuan, representing over 70% of the total procurement value and making them the dominant dosage form in this round of procurement.
Industry insiders said that this round of centralized procurement has achieved breakthroughs both in the number of drug varieties and in the scale of drugs procured. Moreover, unlike previous national centralized procurements in which injectables had a procurement cycle of only one year, the procurement cycle for injectables in this round is the same as that for oral formulations. The longer procurement cycle has further intensified competition among market players and enterprises.

The national centralized drug procurement program serves as a crucial indicator of the pharmaceutical industry’s business trends, directly influencing pharmaceutical companies’ product R&D and production operations. It thus receives close attention from both pharmaceutical firms and society at large. Passing the evaluation of bioequivalence and therapeutic equivalence for generic drugs is an important pathway for pharmaceutical companies to participate in the national centralized drug procurement and accelerate their market entry. In recent years, Shijiazhuang Fourth Pharmaceutical has established an innovative “four-wheel-drive” strategy that synergistically promotes consistency evaluation research alongside the development of innovative drugs, generic drugs, and active pharmaceutical ingredients. As a result, its innovative achievements have been steadily accumulating and now are beginning to yield significant results. To date, Shijiazhuang Fourth Pharmaceutical has had 13 drug varieties—totaling 18 specifications—successfully pass the national evaluation of bioequivalence and therapeutic equivalence for generic drugs or be deemed as having passed such evaluations. The number and pace of these approvals place it among the industry leaders.

Keywords:

Big News! Shijiazhuang Sihua Pharmaceutical’s azithromycin injection (0.5g and 0.25g) has received approval for a supplemental drug application, making the company the marketing authorization holder for this product.

Shijiazhuang No.4 Pharmaceutical Co., Ltd. signed a strategic cooperation framework agreement with the North China Branch of Sinopec Chemical Sales Co., Ltd.